Search

everythinglearnresearchcommunity

for

Search:↓

Plasmacytoid dendritic cells, which overproduce IFN-α, may play a crucial role in starting alopecia areata, an autoimmune disease causing hair loss.

Many treatments for alopecia areata have inconsistent results; for under 10s, use minoxidil with a corticosteroid, and for over 10s, add ILC and consider diphenylcyclopropenone for widespread cases.

Blood tests can help understand the genetic differences in people with alopecia areata, including how severe it is and if it's inherited.

A kidney transplant patient on cyclosporin experienced unexpected severe hair loss, which improved with treatment adjustments.

Alopecia areata may lead to hearing loss.

A woman with alopecia regrew her hair after taking a higher dose of tocilizumab.

Stressful life events may trigger alopecia areata.

Topical corticosteroids are the preferred first treatment for children with Alopecia Areata.

Managing alopecia areata in children needs a personalized approach considering genetic, immune, and environmental factors.

Alopecia areata leads to significantly higher healthcare costs due to more doctor visits and prescriptions.

Use specific tools to measure quality of life in alopecia areata patients and improve future treatments.

Hair and serum levels of zinc, copper, and iron are similar in people with alopecia areata and healthy individuals.

New protein changes may be involved in the immune attack on hair follicles in alopecia areata.

Certain genetic variants linked to immune response increase the risk of alopecia areata in Taiwanese people.

Leflunomide is more likely to help treat alopecia areata than cause it.

Platelet-rich plasma treatment is not very effective for chronic severe alopecia areata.

Alopecia areata patients may have higher blood pressure and blood sugar, indicating a future risk of metabolic issues.

Patients using social media have mixed feelings about alopecia treatments, noting hair growth but also frustration with treatment recurrence.

There is no significant link between alopecia areata and the PON1 enzyme polymorphisms studied.

ILC1-like cells can cause alopecia areata by attacking hair follicles.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

Alopecia areata patients have higher IgE and IL-13 levels, suggesting immune involvement.

Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.

Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.

The study suggested certain immune cells might cause alopecia areata, but it was retracted.

Activating Tgr5 may help treat hair loss and bone loss.

Vitamin A may influence hair loss conditions like alopecia, but more research is needed to understand how.

Certain bacteria may influence alopecia areata risk, but skin bacteria don't mediate gut-skin effects.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.